Trial Condition(s):
Real-world comparative effectiveness of Dabigatran versus Vitamin K antagonist (DABI-F)
18732
Not Available
Not Available
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
- Non-valvular atrial fibrillation will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD-9 427.31 (International Classification of Disease, Ninth Revision, Clinical Modification) as the diagnosis code at any time in the patient’s data history prior to inclusion - Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics - CHA2DS2-Vasc (Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65–74 years; Sc: Sex category ) score ≥2 during the 180 days prior to index dabigatran use baseline period
- Patients <18 years of age - Patients with valvular Atrial fibrillation - Pregnancy - Malignant cancers - Transient cause of Atrial fibrillation - Patients with Venous thromboembolism (pulmonary embolism or Deep Vein Thrombosis) - Patients with major surgery defined as hip or knee replacement - Prescriptions of Oral anticoagulants (OACs) {apixaban, warfarin, dabigatran, rivaroxaban} before index date - Prescription of more than one OAC on the index date - Patient with any of the events defined in the composite endpoint
Locations | |
---|---|
Locations Investigative Site New York, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Real-world comparative effectiveness of Dabigatran versus VKA
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2